Additionally, genomically annotated cohorts of CRPC and EGFR-mutant lung cancer reveal that not all adenocarcinomas with RB1 and TP53 loss undergo lineage transition in response to therapy (12, 14). This evidence concerns the gene TP53 and lung carcinoma.